Leukemia inhibitory factor (LIF) modulates pro-opiomelanocortin (POMC) gene regulation in stably transfected AtT-20 cells overexpressing LIF
- PMID: 9657069
- DOI: 10.1007/BF02801326
Leukemia inhibitory factor (LIF) modulates pro-opiomelanocortin (POMC) gene regulation in stably transfected AtT-20 cells overexpressing LIF
Abstract
Leukemia inhibitory factor (LIF) levels are elevated in sepsis and correlate with shock and poor prognosis. We have previously shown that lipopolysaccharide (LPS) administration induces hypothalamic and pituitary LIF expression in vivo, which is associated with the acute rise in circulating adrenocorticotrophic hormone (ACTH) levels. As AtT-20 cells respond to LIF, we established murine LIF (mLIF) stably transfected AtT-20 cell lines to study LIF regulation of pro-opiomelanocortin (POMC) expression and ACTH secretion. Our results show that mLIF transfectants accumulated mLIF (up to 15.6 +/- 3.2 ng/mL after 24 h) as well as increased ACTH secretion (up to 2.4-fold above control cells) in conditioned medium. The magnitude of ACTH induction correlated with mLIF concentrations in different transfectants (r = 0.75-0.88, p < 0.05). Moreover, mLIF transfectants showed a higher sensitivity to CRH stimulation with an increased ACTH production within 8 h (p < 0.05), whereas control cells were responsive to CRH at 24 h. Additionally, mLIF transfectants exhibited a maximum threefold ACTH induction, compared to 1.7-fold in control cells. Furthermore, mLIF transfectants have a blunted dexamethasone-mediated inhibition of ACTH (35% inhibition in control cells vs no inhibition in mLIF-transfected cells at 24 h). These findings support and extend the previous observations of LIF acting at the pituitary level, and indicate that mLIF stably-transfected AtT-20 cells are a useful model for studying mLIF-mediated gene regulation in pituicytes.
Similar articles
-
Human and murine pituitary expression of leukemia inhibitory factor. Novel intrapituitary regulation of adrenocorticotropin hormone synthesis and secretion.J Clin Invest. 1995 Mar;95(3):1288-98. doi: 10.1172/JCI117779. J Clin Invest. 1995. PMID: 7883977 Free PMC article.
-
Leukemia inhibitory factor (LIF) stimulates proopiomelanocortin (POMC) expression in a corticotroph cell line. Role of STAT pathway.J Clin Invest. 1996 Apr 15;97(8):1852-9. doi: 10.1172/JCI118615. J Clin Invest. 1996. PMID: 8621768 Free PMC article.
-
Pituitary corticotroph SOCS-3: novel intracellular regulation of leukemia-inhibitory factor-mediated proopiomelanocortin gene expression and adrenocorticotropin secretion.Mol Endocrinol. 1998 Jul;12(7):954-61. doi: 10.1210/mend.12.7.0140. Mol Endocrinol. 1998. PMID: 9658400
-
The unsolved enigmas of leukemia inhibitory factor.Stem Cells. 2003;21(1):5-14. doi: 10.1634/stemcells.21-1-5. Stem Cells. 2003. PMID: 12529546 Review.
-
Leukemia inhibitory factor as an intrapituitary regulator of pro-opiomelanocortin gene expression and corticotrope ontogeny.Eur J Endocrinol. 1999 Sep;141(3):214-5. doi: 10.1530/eje.0.1410214. Eur J Endocrinol. 1999. PMID: 10474116 Review. No abstract available.
Cited by
-
Morphine treatment selectively regulates expression of rat pituitary POMC and the prohormone convertases PC1/3 and PC2.Peptides. 2013 Sep;47:99-109. doi: 10.1016/j.peptides.2013.07.006. Epub 2013 Jul 26. Peptides. 2013. PMID: 23891651 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous